Cargando…
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...
Autores principales: | Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861222/ https://www.ncbi.nlm.nih.gov/pubmed/26679970 http://dx.doi.org/10.18553/jmcp.2015.21.12.1214 |
Ejemplares similares
-
Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
por: Florez, H, et al.
Publicado: (2015) -
Accuracy and completeness of mortality data in the Department of Veterans Affairs
por: Sohn, Min-Woong, et al.
Publicado: (2006) -
Outcomes of Veterans Treated in Veterans Affairs Hospitals vs Non–Veterans Affairs Hospitals
por: Yoon, Jean, et al.
Publicado: (2023) -
Antibiotic Prescribing by Dentists and Geographic Variability in the Veterans Affairs (VA) Health System
por: Acosta, Kaitlyn, et al.
Publicado: (2017) -
Choosing Veterans Affairs: Determinants of post-9/11 Veterans’ enrollment in Veterans Affairs health care
por: Vanneman, Megan E., et al.
Publicado: (2023)